Methods of treating asthma with polypeptides targeting IL-13 and TSLP

1. A method of treating asthma, wherein said method comprises administering, to a subject in need thereof, an effective amount of a polypeptide that comprises at least one immunoglobulin single variable domain (ISVD) that specifically binds to IL13 or TSLP, wherein said ISVD comprises three complementarity determining regions (CDR1 to CDR3, respectively); and wherein the at least one ISVD comprises:

a) a CDR1 that comprises the amino acid sequence of SEQ ID NO: 7;

a CDR2 that comprises the amino acid sequence of SEQ ID NO: 12; and

a CDR3 that comprises the amino acid sequence of SEQ ID NO: 17,

b) a CDR1 that comprises the amino acid sequence of SEQ ID NO: 8;

a CDR2 that comprises the amino acid sequence of SEQ ID NO: 13; and

a CDR3 that comprises the amino acid sequence of SEQ ID NO: 18,

c) a CDR1 that comprises the amino acid sequence of SEQ ID NO: 9;

a CDR2 that comprises the amino acid sequence of SEQ ID NO: 14; and

a CDR3 that comprises the amino acid sequence of SEQ ID NO: 19, or

d) a CDR1 that comprises the amino acid sequence of SEQ ID NO: 11;

a CDR2 that comprises the amino acid sequence of SEQ ID NO: 16; and

a CDR3 that comprises the amino acid sequence of SEQ ID NO: 21.

2. The method according to claim 1 , wherein said at least one IS VD that specifically binds to IL-13 or TSLP comprises:

a) the amino acid sequence of SEQ ID NO: 2,

b) the amino acid sequence of SEQ ID NO: 3,

c) the amino acid sequence of SEQ ID NO: 4, or

d) the amino acid sequence of SEQ ID NO: 6.

3. The method according to claim 1 , wherein the polypeptide comprises at least two ISVDs, wherein each of said ISVDs comprises three complementarity determining regions (CDR1 to CDR3, respectively), and wherein:

a) a first and a second ISVD specifically binds to IL-13 and comprises

i. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 7;

ii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 12; and

iii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 17,

b) a first and a second ISVD specifically binds to IL-13 and comprises

i. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 8;

ii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 13; and

iii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 18,

c) a first ISVD specifically binds to IL-13 and comprises

i. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 7;

ii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 12; and

iii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 17, and

a second ISVD specifically binds to IL-13 and comprises

iv. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 8;

v. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 13; and

vi. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 18,

d) a first ISVD specifically binds to IL-13 and comprises

i. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 8;

ii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 13; and

iii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 18, and

a second ISVD specifically binds to IL-13 and comprises

iv. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 7;

v. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 12; and

vi. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 17,

e) a first ISVD specifically binds to TSLP and comprises

i. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 11;

ii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 16; and

iii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 21, and

a second ISVD specifically binds to TSLP and comprises

iv. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 9;

v. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 14; and

vi. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 19, or

f) a first ISVD specifically binds to TSLP and comprises

i. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 9;

ii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 14; and

iii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 19, and

a second ISVD specifically binds to TSLP and comprises

iv. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 11;

v. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 16; and

vi. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 21,

wherein the order of the ISVDs indicates their relative position to each other considered from the N-terminus to the C-terminus of said polypeptide.

4. The method according to claim 3 , wherein the polypeptide comprises:

a) the amino acid sequence of SEQ ID NO: 148,

b) the amino acid sequence of SEQ ID NO: 149,

c) the amino acid sequence of SEQ ID NO: 150,

d) the amino acid sequence of SEQ ID NO: 151,

e) the amino acid sequence of SEQ ID NO: 152,

f) the amino acid sequence of SEQ ID NO: 153,

g) the amino acid sequence of SEQ ID NO: 154,

h) the amino acid sequence of SEQ ID NO: 155,

i) the amino acid sequence of SEQ ID NO: 156,

j) the amino acid sequence of SEQ ID NO: 157,

k) the amino acid sequence of SEQ ID NO: 158, or

l) the amino acid sequence of SEQ ID NO: 159.

5. The method of claim 3 , wherein the at least two ISVDs are linked via one or more peptidic linkers.

6. The method according to claim 1 , wherein the polypeptide comprises at least four ISVDs, wherein each of said ISVDs comprises three complementarity determining regions (CDR1 to CDR3, respectively), and wherein:

a) a first ISVD specifically binds to IL-13 and comprises

i. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 7;

ii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 12; and

iii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 17,

b) a second ISVD specifically binds to IL-13 and comprises

iv. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 8;

v. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 13; and

vi. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 18,

c) a third ISVD specifically binds to TSLP and comprises

vii. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 9;

viii. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 14; and

ix. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 19, and

d) a fourth ISVD specifically binds to TSLP and comprises

x. a CDR1 that comprises the amino acid sequence of SEQ ID NO: 11;

xi. a CDR2 that comprises the amino acid sequence of SEQ ID NO: 16; and

xii. a CDR3 that comprises the amino acid sequence of SEQ ID NO: 21,

wherein the order of the ISVDs indicates their relative position to each other considered from the N-terminus to the C-terminus of said polypeptide.

7. The method according to claim 6 , wherein:

a) said first ISVD comprises the amino acid sequence of SEQ ID NO: 2;

b) said second ISVD comprises the amino acid sequence of SEQ ID NO: 3;

c) said third ISVD comprises the amino acid sequence of SEQ ID NO: 4; and

d) said fourth ISVD comprises the amino acid sequence of SEQ ID NO: 6.

8. The method according to claim 6 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1.

9. The method according to claim 8 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1.

10. The method of claim 6 , wherein the at least four ISVDs are linked via one or more peptidic linkers.

11. The method according to claim 1 , wherein said polypeptide further comprises one or more other groups, residues, moieties or binding units, in which said one or more other groups, residues, moieties or binding units provide the polypeptide with increased half-life, compared to the corresponding polypeptide without said one or more other groups, residues, moieties or binding units.

12. The method according to claim 11 , in which said one or more other groups, residues, moieties or binding units that provide the polypeptide with increased half-life is selected from the group consisting of binding units that bind to serum albumin and a serum immunoglobulin.

13. The method according to claim 12 , in which said binding unit that provides the polypeptide with increased half-life is an ISVD that binds to human serum albumin, wherein the ISVD that binds to human serum albumin comprises a CDR1 that comprises the amino acid sequence of SEQ ID NO: 10, a CDR2 that comprises the amino acid sequence of SEQ ID NO: 15 and a CDR3 that comprises the amino acid sequence of SEQ ID NO: 20.

14. The method according to claim 13 , wherein the amino acid sequence of said ISVD binding to human serum albumin comprises a sequence identity of more than 90% with SEQ ID NO: 5.

15. The method according to claim 13 , wherein said ISVD binding to human serum albumin comprises the amino acid sequence of SEQ ID NO: 5.

16. The method claim 12 , wherein the serum immunoglobulin is an IgG.

17. The method of claim 11 , wherein the one or more other groups, residues, moieties or binding units one or more other groups, residues, moieties or binding units are linked to an ISVD of the polypeptide via one or more peptidic linkers.

18. The method according to claim 1 , wherein the polypeptide is in a pharmaceutical composition.